在患有直肠癌的患者对化疗完全反应后,罕见的复发模式:病例报告
Masatoshi Nomura1, Mitsuyoshi Tei2, Takayoshi Goto3
1Department of Gastroenterological Surgery, Osaka Rosai Hospital, Nagasone 1179-3, Kita Ward, Sakai, Osaka, 591-8025, Japan. mnomura64@gmail.com.
Surgical case reports
|May 7, 2024
概括
本病例报告详细介绍了一些罕见的晚期门癌 (IVa阶段) 在初始化疗反应后的几年内扩散到膀,小肠和皮肤. 它突出了门癌的异常转移模式.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 胃肠病学 胃肠病学
背景情况:
- 大肠直肠癌通常会转移到肝脏,肺部,淋巴结和腹膜.
- 门癌很少转移到膀,小肠和皮肤.
研究的目的:
- 报告一个罕见的晚期门癌症病例,异常的转移部位.
- 在初始治疗后记录癌转移的进展.
主要方法:
- 一名66岁的男性患有临床IVa期门癌,接受化疗并接受机器人辅助腹腔镜手术.
- 手术后的随访包括CT扫描,活检和进一步的化疗.
- 组织病理学评估证实了膀,小肠和皮肤的转移.
主要成果:
- 患者出现门癌和肝转移,获得了化学疗法的临床完整反应.
- 在手术后18个月,在膀壁被诊断出复发的门癌症.
- 随后的小肠和皮肤转移得到证实,导致患者死亡.
结论:
- 这一案例说明了临床IVa期门癌的罕见表现,该癌症转移到膀壁,小肠和皮肤.
- 它强调了在晚期门癌中考虑不寻常的转移部位的重要性,即使在初始治疗反应后也是如此.
更多相关视频
08:26Clinical Application of Single-Surgeon, Three-Port, Laparoscopic Resection for Colorectal Cancer with Natural Orifice Specimen Extraction
Published on: March 24, 2023
458
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
256
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...